{"annotatable":{"parts":["s1v1","s2v1","s3v1","s4v1","s5v1","s6v1","s7v1","s8v1","s9v1","s10v1","s11v1","s12v1","s13v1","s14v1","s15v1","s16v1","s17v1","s18v1"]},"anncomplete":true,"sources":[],"metas":{"m_82":{"value":"Some-concerns","confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1}},"m_83":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1}},"m_84":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1}},"m_85":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1}},"m_86":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1}},"m_35":{"value":"Some-concerns","confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1}}},"entities":[{"classId":"e_109","part":"s1v1","offsets":[{"start":13,"text":"A Randomized Controlled Trial"}],"coordinates":[],"confidence":{"state":"pre-added","who":["ml:regex"],"prob":0.5},"fields":{},"normalizations":{}},{"classId":"e_128","part":"s1v1","offsets":[{"start":2823,"text":"F"}],"coordinates":[],"confidence":{"state":"pre-added","who":["ml:regex"],"prob":0.5},"fields":{},"normalizations":{}},{"classId":"e_109","part":"s3v1","offsets":[{"start":1562,"text":"a randomized controlled trial"}],"coordinates":[{"x":"205.55","y":"348.27"},{"x":"321.36","y":"354.84"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_128","part":"s3v1","offsets":[{"start":1658,"text":"comprehensive intensive management of cardiovascular disease (CVD)risk factors by a NP/CHW team or an enhanced usual care (EUC) control group. Individualsin the control group received usual care from their primary provider which was enhanced byfeedback regarding CVD risk factors provided to the patient and their provider. Those in theintensive intervention group received enhanced usual care plus management by the NP/CHW team"}],"coordinates":[{"x":"227.77","y":"360.27"},{"x":"195.27","y":"426.84"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_117","part":"s4v1","offsets":[{"start":220,"text":"participants were randomly assigned, stratified by race and sex,"}],"coordinates":[{"x":"150.00","y":"108.27"},{"x":"403.83","y":"114.84"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_180","part":"s5v1","offsets":[{"start":2455,"text":"primary outcomes were changes from baseline to one year in lipids, BP, HbA1c andpatients’ perceptions of the quality of their chronic illness care"}],"coordinates":[{"x":"168.05","y":"490.27"},{"x":"400.23","y":"508.84"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_180","part":"s5v1","offsets":[{"start":2754,"text":"HbA1c < 7% or clinically significant decrease of ≥0.5%; systolic BP < 140 mm Hg or < 130 mm Hg if patient had diabetes or kidney diseaseor clinically significant decrease of ≥ 10 mm Hg; and LDL cholesterol level, < 100 mg/dLor < 130 if no CVD or diabetes or a clinically significant decrease of ≥ 20%"}],"coordinates":[{"x":"311.37","y":"526.27"},{"x":"454.41","y":"568.84"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_210","part":"s5v1","offsets":[{"start":2754,"text":"HbA1c < 7% or clinically significant decrease of ≥0.5%; systolic BP < 140 mm Hg or < 130 mm Hg if patient had diabetes or kidney diseaseor clinically significant decrease of ≥ 10 mm Hg; and LDL cholesterol level, < 100 mg/dLor < 130 if no CVD or diabetes or a clinically significant decrease of ≥ 20%"}],"coordinates":[{"x":"311.37","y":"526.27"},{"x":"454.41","y":"568.84"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_204","part":"s5v1","offsets":[{"start":2754,"text":"HbA1c < 7% or clinically significant decrease of ≥0.5%; systolic BP < 140 mm Hg or < 130 mm Hg if patient had diabetes or kidney diseaseor clinically significant decrease of ≥ 10 mm Hg; and LDL cholesterol level, < 100 mg/dLor < 130 if no CVD or diabetes or a clinically significant decrease of ≥ 20%"}],"coordinates":[{"x":"311.37","y":"526.27"},{"x":"454.41","y":"568.84"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_192","part":"s5v1","offsets":[{"start":3056,"text":"The chemistrylaboratory at Johns Hopkins performed all biochemical measures"}],"coordinates":[{"x":"459.41","y":"562.27"},{"x":"410.23","y":"580.84"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_185","part":"s5v1","offsets":[{"start":3133,"text":"Total cholesterol,triglycerides, and high-density lipoprotein cholesterol (HDL-C) were measured directly aftera 12 hour fast. Low-density lipoprotein cholesterol (LDL-C) was estimated using theFriedewald equation.31 In the event of triglyceride levels greater than 400 mg/dL, directmeasurement of LDL-C through ultracentrifugation methods was performed. In participantswith diabetes, HbA1c was measured using high pressure liquid chromatography. Bloodpressure was measured using the Omron Digital Blood Pressure Monitor HEM-907XLautomatic blood pressure device according to JNC VII guidelines, following five minutes ofquiet rest, in the right arm with the person seated in a chair with arm supported at heartlevel. The average of three blood pressures was recorded."}],"coordinates":[{"x":"415.23","y":"574.27"},{"x":"379.92","y":"688.84"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_180","part":"s6v1","offsets":[{"start":0,"text":"The patient’s ratings of care received from their health care team was measured by thePatient Assessment of Chronic Illness Care (PACIC) Survey"}],"coordinates":[{"x":"150.00","y":"62.27"},{"x":"392.48","y":"80.84"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_185","part":"s6v1","offsets":[{"start":0,"text":"The patient’s ratings of care received from their health care team was measured by thePatient Assessment of Chronic Illness Care (PACIC) Survey"}],"coordinates":[{"x":"150.00","y":"62.27"},{"x":"392.48","y":"80.84"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_148","part":"s6v1","offsets":[{"start":2035,"text":"Analysis followed the intention- to- treat modelincluding all randomized participants in the analyses according to their original assignment."}],"coordinates":[{"x":"324.68","y":"408.27"},{"x":"517.18","y":"426.84"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_204","part":"s6v1","offsets":[{"start":2677,"text":"Generalized linear mixed models (GLMM) using a random patient-level intercept modelwere used to build multilevel models comparing the effectiveness of the NP/CHWintervention with EUC on each outcome, controlling for the covariates of age, sex, race,body mass index, insurance status which were determined by univariate analyses to bepredictive of outcomes."}],"coordinates":[{"x":"150.00","y":"514.27"},{"x":"244.15","y":"568.84"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_210","part":"s7v1","offsets":[{"start":912,"text":"(Table 2)."}],"coordinates":[{"x":"212.21","y":"214.27"},{"x":"251.64","y":"220.84"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_215","part":"s7v1","offsets":[{"start":923,"text":"The analyses using general linear mixed models controlled forage, sex, education, race, body mass index, insurance status, and an indicator of controlstatus at baseline. The estimated between group differences were clinically significant. Atthe 12 month follow-up, a significantly higher percentage of patients in the interventiongroup compared to the EUC group had values that reached guideline goals or showedclinically significant improvements in LDL cholesterol (EUC=58%; I=75%, p<0.001),systolic BP (EUC=74%; I=82%, p=0.018), and HbA1c (EUC=47%; I=60%, p=0.016)"}],"coordinates":[{"x":"254.14","y":"214.27"},{"x":"493.81","y":"292.84"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_135","part":"s13v1","offsets":[{"start":0,"text":"Figure 1.CONSORT diagram of COACH Trial"}],"coordinates":[{"x":"150.00","y":"364.55"},{"x":"302.21","y":"381.55"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_158","part":"s13v1","offsets":[{"start":0,"text":"Figure 1.CONSORT diagram of COACH Trial"}],"coordinates":[{"x":"150.00","y":"364.55"},{"x":"302.21","y":"381.55"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_120","part":"s14v1","offsets":[{"start":132,"text":"Characteristic Intervention (n = 261) Usual Care (n = 264) PAge, y, mean (SD)* 54.3 (12.0) 54.7 (11.5) 0.692Female, n (%) 187 (71.7) 187 (70.8) 0.837Marital status, n (%) 0.591  Single 61 (23.4) 69 (26.1)  Married 86 (33.0) 80 (30.3)  Separated 19 (7.3) 28 (10.6)  Widowed 39 (14.9) 37 (14.0)  Divorced 56 (21.5) 50 (18.9)Race, n (%) 0.946  Non-black 54 (20.7) 54 (20.5)  Black 207 (79.3) 210 (79.6)Education, n (%) 0.051  <High School 76 (29.1) 94 (35.6)  High school/GED 118 (45.2) 92 (34.9)  Some college 67 (25.7) 78 (29.6)Employment status, n (%) 0.318  Employed 110 (42.2) 100 (37.9)  Not employed 151 (57.9) 164 (62.1)Type of insurance, n (%) 0.403  Private 112 (42.9) 105 (39.8)  Medicare and/or Medicaid 106 (40.6) 101 (38.3)  Uninsured 43 (16.5) 55 (20.8)  Unknown 0 (0) 3 (1.1)Annual income, n (%) 0.223  <$20,000 137 (52.5) 149 (56.4)  ≥$20,000 120 (46.0) 105 (39.8)  Unknown 4 (1.5) 10 (3.8)Comorbidity score, mean (SD) 1.6 (1.3) 1.8)1.4) 0.193Diastolic Blood Pressure, mean (SD) 83.1 (12.6) 82.3 (13.0) 0.442Systolic Blood Pressure, mean (SD) 139.7 (23.8) 138.7 (19.9) 0.587Total Cholesterol, mean (SD) 199.7 (46.0) 191.3 (45.0) 0.036LDL-C†, mean (SD) 121.6 (40.0) 116.3 (40.5) 0.132HDL-C‡, mean (SD) 50.8 (14.7) 50.9 (13.6) 0.92Triglycerides, median (IQR)§ 113 (85) 105 (76) 0.220Hemoglobin A1c, mean (SD) 8.9 (2.2) 8.3 (1.9) 0.006PACIC||, mean (SD) 1.5 (0.9) 1.6 (0.9) 0.883"}],"coordinates":[{"x":"83.00","y":"122.63"},{"x":"377.57","y":"641.63"}],"confidence":{"state":"pre-added","who":["user:rahel-caliesch"],"prob":1},"fields":{},"normalizations":{}}],"relations":[]}